

1. *Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction*
Deuse, T., et al.
Circulation, 2009. **120**(11 Suppl): p. S247-54.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19752375
2. *Increased expression of integrin-linked kinase attenuates left ventricular remodeling and improves cardiac function after myocardial infarction*
Ding, L., et al.
Circulation, 2009. **120**(9): p. 764-73.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19687354
3. *Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase*
Fischer, K.M., et al.
Circulation, 2009. **120**(21): p. 2077-87.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19901187
4. *Novel minicircle vector for gene therapy in murine myocardial infarction*
Huang, M., et al.
Circulation, 2009. **120**(11 Suppl): p. S230-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19752373
5. *Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms*
Lahteenvuo, J.E., et al.
Circulation, 2009. **119**(6): p. 845-56.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19188502
6. *Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study*
Lau, D.H., et al.
Circulation, 2009. **119**(1): p. 19-27.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19103989

7. *Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor- κ B-dependent pathway*

Li, Q., et al.

Circulation, 2009. **120**(13): p. 1222-30.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19752329

8. *Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization*

Loinard, C., et al.

Circulation, 2009. **120**(1): p. 50-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19546390

9. *Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor*

Pinkert, S., et al.

Circulation, 2009. **120**(23): p. 2358-66.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19933937

10. *Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure*

Rengo, G., et al.

Circulation, 2009. **119**(1): p. 89-98.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19103992

11. *Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy*

Suckau, L., et al.

Circulation, 2009. **119**(9): p. 1241-52.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19237664

12. *Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial*

Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction

Taljaard, M., et al.

Am Heart J, 2010. **159**(3): p. 354-60.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20211295